1. Home
  2. BNL vs ACAD Comparison

BNL vs ACAD Comparison

Compare BNL & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Broadstone Net Lease Inc.

BNL

Broadstone Net Lease Inc.

HOLD

Current Price

$17.39

Market Cap

3.7B

Sector

Real Estate

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$19.74

Market Cap

4.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNL
ACAD
Founded
2007
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
4.4B
IPO Year
2008
2000

Fundamental Metrics

Financial Performance
Metric
BNL
ACAD
Price
$17.39
$19.74
Analyst Decision
Buy
Buy
Analyst Count
11
20
Target Price
$23.60
★ $30.53
AVG Volume (30 Days)
1.9M
★ 2.1M
Earning Date
10-28-2026
11-04-2026
Dividend Yield
★ 6.67%
N/A
EPS Growth
N/A
★ 69.12
EPS
★ 0.24
0.20
Revenue
$454,138,000.00
★ $726,437,000.00
Revenue This Year
$8.13
$18.71
Revenue Next Year
$9.56
$12.44
P/E Ratio
★ $73.02
$101.40
Revenue Growth
5.17
★ 40.45
52 Week Low
$17.13
$18.39
52 Week High
$23.10
$30.96

Technical Indicators

Market Signals
Indicator
BNL
ACAD
Relative Strength Index (RSI) 30.13 36.18
Support Level N/A $18.39
Resistance Level $18.81 $22.92
Average True Range (ATR) 0.44 0.59
MACD -0.01 0.35
Stochastic Oscillator 14.48 61.01

Price Performance

Historical Comparison
BNL
ACAD

About BNL Broadstone Net Lease Inc.

Broadstone Net Lease Inc is an internally managed real estate investment trust that invests in, owns, and manages single-tenant commercial real estate properties that are net leased on a long-term basis to a diversified group of tenants. The company has selectively invested in net leased assets in the industrial, healthcare, restaurant, retail, and office property types. The company focuses on investing in real estate that is operated by creditworthy single tenants in industries characterized by positive business drivers and trends. The company targets properties that are an integral part of the tenants' businesses and are therefore opportunities to secure long-term net leases.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: